What is Opertech Bio?
Opertech Bio specializes in innovative taste testing services and licensing, targeting the multi-billion dollar food and beverage, flavor ingredient, and pharmaceutical industries. Their patented TāStation technology allows for rapid and accurate measurement of taste characteristics across numerous samples, significantly enhancing product development timelines. The company serves a diverse clientele, including some of the largest food, beverage, consumer healthcare, and pharmaceutical companies globally. Opertech Bio is recognized for its ability to deliver exceptional results in taste research and sensory innovation.
How much funding has Opertech Bio raised?
Opertech Bio has raised a total of $813K across 2 funding rounds:
Private Equity
$750K
Debt
$63K
Private Equity (2014): $750K with participation from Gabriel Investments
Debt (2021): $63K led by PPP
Key Investors in Opertech Bio
PPP
Public-Private Partnership
Gabriel Investments
Gabriel Investments is an investment group focused on supporting high-potential businesses in the Philadelphia region. With a team of founders and operators, they invest in and advise early-stage technology companies, particularly those that are post-revenue and poised for growth.
What's next for Opertech Bio?
With the recent substantial expansion capital, Opertech Bio is poised to scale its operations and further develop its TāStation technology. This major enterprise-level funding will likely be directed towards enhancing research and development capabilities, expanding market reach, and potentially forging new strategic partnerships within the food, beverage, and pharmaceutical industries. The company's focus on data-driven taste analysis positions it to capitalize on the growing demand for precise and efficient product development solutions.
See full Opertech Bio company page
